Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare

Derek Sarovich; Linda Ward; Erin Price; Mark Mayo; Matthew Pitman; Robert Baird; Bart Currie

doi:10.1128/JCM.02239-13

Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare

Derek Sarovich, Linda Ward, Erin Price, Mark Mayo, Matthew Pitman, Robert Baird, Bart Currie

Research output: Contribution to journal › Article

27 Citations (Scopus)

Abstract

The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.

Original language	English
Pages (from-to)	650-653
Number of pages	4
Journal	Journal of Clinical Microbiology
Volume	52
Issue number	2
DOIs	https://doi.org/10.1128/JCM.02239-13
Publication status	Published - 2014

Access to Document

10.1128/JCM.02239-13

Fingerprint Dive into the research topics of 'Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare'. Together they form a unique fingerprint.

Cite this

Sarovich, D., Ward, L., Price, E., Mayo, M., Pitman, M., Baird, R., & Currie, B. (2014). Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. Journal of Clinical Microbiology, 52(2), 650-653. https://doi.org/10.1128/JCM.02239-13

@article{3449ba7ddfcc4b279ea585ea97fb9cf3,

title = "Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare",

abstract = "The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.",

author = "Derek Sarovich and Linda Ward and Erin Price and Mark Mayo and Matthew Pitman and Robert Baird and Bart Currie",

year = "2014",

doi = "10.1128/JCM.02239-13",

language = "English",

volume = "52",

pages = "650--653",

journal = "Journal of Clinical Microbiology",

issn = "0095-1137",

publisher = "American Society of Microbiology",

number = "2",

}

TY - JOUR

T1 - Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare

AU - Sarovich, Derek

AU - Ward, Linda

AU - Price, Erin

AU - Mayo, Mark

AU - Pitman, Matthew

AU - Baird, Robert

AU - Currie, Bart

PY - 2014

Y1 - 2014

N2 - The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.

AB - The Darwin Prospective Melioidosis Study has documented 785 melioidosis cases over 23 years. Recurrent melioidosis occurred in 39/679 (5.7%) patients surviving initial infection; 29 patients suffered relapse of the original infection, and 10 presented with a new Burkholderia pseudomallei infection. With improved therapy, relapse has become rare in recent years.

U2 - 10.1128/JCM.02239-13

DO - 10.1128/JCM.02239-13

M3 - Article

VL - 52

SP - 650

EP - 653

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -